Dechra Pharmaceuticals PLC Director/PDMR Shareholding (7756V)
16 Aprile 2021 - 2:45PM
UK Regulatory
TIDMDPH
RNS Number : 7756V
Dechra Pharmaceuticals PLC
16 April 2021
16 April 2021
Dechra Pharmaceuticals PLC
Notification of Transactions by Persons Discharging Managerial
Responsibilities
On 16 April 2021, Dechra Pharmaceuticals PLC was notified by a
Director of the Company and Person Discharging Managerial
Responsibilities that he had completed the sale of part of his
beneficial interest in Dechra.
Tony Griffin, Executive Director, has sold 25,000 ordinary
shares in the Company to satisfy long term personal financial
planning considerations and widen his investment portfolio.
Following this transaction, Tony Griffin will continue to retain a
beneficial holding of 45,650 ordinary shares which represents
0.042% of the current issued share capital in the Company.
The Notification of Dealing Form set out below is provided in
accordance with the UK Market Abuse Regulation.
Notification of Dealing Form:
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Tony Griffin
--------------------------------------- ----------------------------------
2. Reason for the notification
---------------------------------------------------------------------------
a) Position/status Director
--------------------------------------- ----------------------------------
b) Initial notification/amendment Initial Notification
--------------------------------------- ----------------------------------
3. Details of the Issuer
---------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
--------------------------------------- ----------------------------------
b) LEI code 213800J4UVB5OWG8VX82
--------------------------------------- ----------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
---------------------------------------------------------------------------
a) Description of the financial Ordinary Shares of 1 pence each
instrument ISIN: GB0009633180
Identification code
--------------------------------------- ----------------------------------
b) Nature of the transaction Sale of Shares
--------------------------------------- ----------------------------------
c) Price(s) and volumes(s) Price(s) Volume(s)
GBP 25,000
38.518
--------------------------------------- ---------------- ----------------
d) Aggregated information
* Aggregate volume 25,000
GBP38.518
GBP962,950
* Price
* Total
--------------------------------------- ----------------------------------
e) Date of the transaction 16 April 2021
--------------------------------------- ----------------------------------
f) Place of the transaction London Stock Exchange
--------------------------------------- ----------------------------------
Enquiries:
Dechra Pharmaceuticals PLC
Ian Page, Chief Executive Office: +44 (0) 1606 814 730
Officer
Paul Sandland, Acting Chief Office: +44 (0) 1606 814 730
Financial Officer
e-mail: corporate.enquiries@dechra.com
TooleyStreet Communications
Ltd
Fiona Tooley, Director Office: +44 (0) 121 309 0099
e-mail: fiona@tooleystreet.com Mobile: +44 (0) 7785 703 523
---------------------------------------- ------------------------------
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and
related products business. Our expertise is in the development,
manufacture, and sales and marketing of high quality products
exclusively for veterinarians worldwide. Dechra's business is
unique as the majority of its products are used to treat medical
conditions for which there is no other effective solution or have a
clinical or dosing advantage over competitor products. For more
information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of
Dechra Pharmaceuticals PLC.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHDKABQBBKDBQD
(END) Dow Jones Newswires
April 16, 2021 08:45 ET (12:45 GMT)
Grafico Azioni Dechra Pharmaceuticals (LSE:DPH)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Dechra Pharmaceuticals (LSE:DPH)
Storico
Da Apr 2023 a Apr 2024